Targeting Platform - ‘OptiLinked’ FDCs

Solid tumours require therapies that can penetrate rapidly and completely. ADCs need to be cleared from normal tissues quickly. With its revolutionary OptiLinkTM technology platform, Antikor has adopted an altogether more novel approach for ADCs using much smaller antibody fragments (single-chain scFvs) that are relatively easy to discover and can be bioengineered with a high number of surface lysine residues for multiple drug-molecule conjugation via their -NH2 side-chains. Quite counter-intuitively, this provides far higher payloads loadings on a small fragment than have so far been achieved with whole MAbs, without running the risk of product manufacturing or stability problems.


1. Deonarain MP, Yahioglu G, Stamati I, Marklew J. Emerging formats for next-generation antibody drug conjugates. Expert Opin Drug Discov. 2015 May;10(5):463-81. doi: 10.1517/17460441.2015.1025049










OptiLinked-FDC platform advantages:-